Dividends & Buybacks ·
Cellyan Biotechnology announces a 1-for-20 reverse stock split effective Oct. 26
HKPDCellyan Biotechnology Co., Ltd
Cellyan Biotechnology Co., Ltd announced that its board of directors approved a 1-for-20 reverse stock split of its Class A and Class B ordinary shares. The consolidation is intended to help the company regain compliance with Nasdaq’s minimum bid price requirement for continued listing on the Nasdaq Capital Market. The split will take effect at the opening of market on October 26, 2026, under the symbol HKPD. Fractional shares resulting from the transaction will be rounded up to the nearest whole share. The company operates in the OTC pharmaceutical cross-border e-commerce supply chain services industry.